8-K: Encompass Health Reports Strong Q4 2023 Results and Issues 2024 Guidance

Encompass Health reported a strong finish to 2023 with a 9.6% increase in net operating revenue and Adjusted EBITDA for the fourth quarter, driven by strong discharge growth.

Summary

• Encompass Health reported a 9.6% increase in net operating revenue for the fourth quarter of 2023, reaching $1,246.8 million, compared to $1,137.3 million in the same period of 2022.
• The company's Adjusted EBITDA for Q4 2023 also increased by 9.6% to $255.0 million, up from $232.7 million in Q4 2022.
• Adjusted earnings per share for the quarter were $0.95, an 8.0% increase from $0.88 in the prior year.
• Discharges increased by 8.3% in Q4 2023, with same-store discharge growth of 5.3%.
• For the full year 2023, net operating revenue grew by 10.4% to $4,801.2 million, and Adjusted EBITDA increased by 18.5% to $971.1 million.
• Adjusted free cash flow for the full year was $525.7 million, a 54.6% increase compared to 2022.
• The company has issued 2024 guidance, projecting net operating revenue between $5,200 and $5,300 million, Adjusted EBITDA between $1,015 and $1,055 million, and adjusted earnings per share between $3.77 and $4.06.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and optimistic guidance. The company is showing good growth and improved financial health, which is favorable for investors.

Positives

• Strong revenue growth driven by increased discharges and a slight increase in net revenue per discharge.
• Significant improvement in Adjusted EBITDA and adjusted free cash flow, indicating improved operational efficiency and profitability.
• Reduction in contract labor expenses, contributing to improved profitability.
• Successful opening of new de novo hospitals and expansion of existing facilities, increasing capacity.
• Decrease in net leverage, demonstrating improved financial health.
• Positive trends in group medical and workers compensation costs.
• The company is providing a positive outlook for 2024 with increased revenue and earnings guidance.

Negatives

• Revenue reserves related to bad debt increased to 4.1% of revenue due to approximately $22 million reserve related to appeals pending before the Departmental Appeals Board (DAB) and various federal district courts.
• There was a 2.2% increase in salaries and wages per FTE (excluding premium labor).
• The company is expecting increased cash taxes in 2024 due to higher net income and the phase-out of bonus depreciation.

Risks

• The company faces risks related to changes in healthcare regulations and reimbursement policies.
• There are competitive pressures in the healthcare industry that could impact the company's performance.
• The company is exposed to risks related to labor costs and shortages of healthcare professionals.
• There are risks associated with integrating acquired operations and completing de novo developments.
• The company is subject to potential disruptions to its information systems and data security.
• There are risks associated with the company's debt obligations and compliance with financial covenants.
• The company is exposed to risks related to the economy and capital markets.

Future Outlook

The company has provided 2024 guidance, projecting net operating revenue between $5,200 and $5,300 million, Adjusted EBITDA between $1,015 and $1,055 million, and adjusted earnings per share between $3.77 and $4.06. They also plan to open 6 de novo hospitals with 280 beds and add approximately 150 beds to existing hospitals.

Management Comments

• The fourth quarter was a very strong finish to 2023, said President and Chief Executive Officer of Encompass Health Mark Tarr.
• Our value proposition and operating strategy continue to be validated and we remain highly optimistic about the long-term prospects of our business.

Industry Context

Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States. The company's performance is influenced by factors such as healthcare regulations, reimbursement policies, and competitive pressures within the healthcare industry. The company's growth strategy includes de novo developments, acquisitions, and joint ventures.

Comparison to Industry Standards

• Encompass Health's same-store discharge growth of 5.3% in Q4 2023 indicates a strong performance compared to the broader healthcare industry, where growth rates can vary significantly.
• The company's Adjusted EBITDA margin of approximately 20.5% for the full year 2023 is a key indicator of profitability and operational efficiency, which is a key metric for comparison with other healthcare providers such as Select Medical and Kindred Healthcare.
• The company's leverage ratio of 2.7x at the end of 2023 is a measure of its financial risk, which is a key metric for comparison with other healthcare providers with similar debt profiles.
• The company's focus on de novo developments and bed additions is a common strategy in the healthcare industry to expand capacity and market share, which is comparable to strategies used by other large healthcare providers.
• The company's ability to reduce contract labor expenses is a positive sign of improved cost management, which is a key challenge for many healthcare providers.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and positive outlook.
• Employees may benefit from the company's growth and improved financial health.
• Customers will benefit from the company's continued investment in high-quality rehabilitative care.
• Suppliers may benefit from the company's increased demand for goods and services.
• Creditors will benefit from the company's improved financial health and reduced leverage.

Next Steps

• The company will host an investor conference call on February 8, 2024, to discuss the Q4 2023 results.
• The company plans to open 6 de novo hospitals with 280 beds and add approximately 150 beds to existing hospitals in 2024.
• The company will continue to pursue its growth strategy through de novo developments, acquisitions, and joint ventures.

Key Dates

Keywords

inpatient rehabilitation, healthcare, financial results, Adjusted EBITDA, revenue, earnings per share, free cash flow, hospital, discharges, guidance